Seeking Alpha

Sucampo Pharmaceuticals slips despite releasing positive top line data

  • Sucampo Pharmaceuticals (SCMP -3.3%) slips today, despite announcing earlier that it had achieved positive top-line results from two recently completed Phase 1a clinical trials of both cobiprostone and SPI-3608.
  • The studies tested the tolerability and pharmacokinetic profiles versus placebo of the two compounds, both of which were demonstrated to be generally well-tolerated in the tested populations.
  • SPI-3608 is being investigated for the treatment of mild to moderate lumbar spinal stenosis and may be investigated for additional indications in the future.
  • The next phase of development for SPI-3608 is expected to begin in the first quarter of 2014.
  • Data on cobiprostone showed that it induces mucosal barrier repair and prevents mucosal barrier damage, and the fact that it was well-tolerated in this study, the company says, is extremely encouraging.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs